Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARO-CFB · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARO-CFB (Healthy Volunteers) | EXPERIMENTAL | 1 or 2 doses of ARO-CFB by subcutaneous (sc) injection |
| Placebo (Healthy Volunteers) | EXPERIMENTAL | placebo calculated volume to match active treatment by sc injection |
| Name | Type | Description |
|---|---|---|
| ARO-CFB | DRUG | ARO-CFB for sc injection |
| Placebo | DRUG | sterile normal saline (0.9% NaCl for sc injection) |
Inclusion Criteria: * Willing to provide written informed consent and to comply with study requirements * Female participants must be non-pregnant/non-lactating * Healthy volunteers must be willing to be vaccinated with a meningococcal and pneumococcal vaccine. IgAN participants must have been vacc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 10 | PHASE3 | BION-1301 |
| Vera Therapeutics, Inc. Class A | VERA | 4 | PHASE3 | Atacicept |
| Travere Therapeutics, Inc. | TVTX | 2 | PHASE3 | sparsentan, irbesartan, Dapagliflozin |
| Biogen Inc. | BIIB | 1 | PHASE3 | Felzartamab |
| AstraZeneca PLC | AZN | 2 | PHASE3 | Ravulizumab |
| Vertex Pharmaceuticals Incorporated | VRTX | 2 | PHASE3 | Povetacicept |
| Biohaven Ltd. | BHVN | 1 | PHASE1 | BHV-1400 |
| Jade Biosciences, Inc. | JBIO | 1 | PHASE2 | JADE101 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-097 |
ARO-CFB is an investigational drug being developed for IgA Nephropathy, a kidney disease. It is currently in Phase 1 clinical development, meaning it has not yet been approved for any use. The drug is being studied in adult healthy volunteers to assess its safety and tolerability.
ARO-CFB is a small molecule being developed by Arrowhead Pharmaceuticals. The specific molecular target of ARO-CFB has not been disclosed in available information. The drug is being studied for its potential role in treating IgA Nephropathy, but its mechanism of action is not publicly detailed.
ARO-CFB is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ARWR. The company is conducting clinical research on this investigational drug for the treatment of IgA Nephropathy.
ARO-CFB is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 study has been completed, and the drug remains in early-stage clinical testing for IgA Nephropathy.
ARO-CFB has one completed clinical trial registered under NCT06209177, titled 'Study of ARO-CFB in Adult Healthy Volunteers.' This Phase 1 study enrolled 49 participants in New Zealand and was a randomized, double-blind, controlled trial. The study is no longer active.
ARO-CFB is the primary name for this investigational drug. No alternative names have been reported in available clinical trial information. It is being studied solely under the identifier ARO-CFB in the context of IgA Nephropathy research.